Expert Interview
Second View: Discussing the Phase 3 results from Ocular Therapeutix on AXPAXLI (OTX-TKI) for the treatment of wet age-related macular degeneration (wAMD)
Ticker(s): OCUL, REGN, RHHBY, EYPTInstitution: Johns Hopkins
- Professor and Chairman of Ophthalmology at Johns Hopkins Bayview Medical Center
- Manages 40 patients per week with geographic atrophy
- Teaches and conducts clinical research that has led to advances in the treatment of complex retinal detachments, vitreo-retinal complications of refractive surgery, diabetic retinopathy and age-related macular degeneration
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Mar 05, 2026
- Call Time
- 07:30 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
